The Entelos Cardiovascular PhysioLab platform was originally built in collaboration with Pfizer.
“The pharmaceutical and medical communities recognize the importance of treating complex conditions much earlier in the disease process,” stated James Karis, president and CEO of Entelos. “We expect to use our new cardiovascular platform to conduct research that goes much deeper into the biology of heart disease to help identify novel approaches and treatments.”